8.2 Axillary Staging: Sentinel Lymph Node Biopsy vs. Axillary Dissection

CBCN Certified Breast Care Nurse Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CBCN Exam

CBCN Exam Facts, 2026 Blueprint & Study Plan

2 Chapter 1: Breast Health, Examination & Benign Conditions (Care Continuum)

1.1 Breast Anatomy, Vascular Supply & Hormonal Physiology 1.2 Clinical Breast Examination & Breast Awareness Education 1.3 Benign Breast Conditions, Mastalgia & Fibrocystic Changes

3 Chapter 2: Screening, Breast Density & Special Populations (Care Continuum)

2.1 Screening Modalities, Breast Density & Pharmacologic Risk Reduction 2.2 Screening & Breast Health in Special Populations

4 Chapter 3: Cancer Risk Assessment & Genetics (Care Continuum)

3.1 Proliferative Lesions, Atypia & High-Risk Benign Pathology 3.2 Breast Cancer Risk Models (Gail, Tyrer-Cuzick, Claus, BRCAPRO) 3.3 Hereditary Cancer Syndromes & Genetic Evaluation

5 Chapter 4: Patient Navigation, Surveillance & Survivorship (Care Continuum)

4.1 Patient Navigation, Barriers to Care, Social Determinants & Interprofessional Collaboration 4.2 Survivorship Care Planning, Surveillance Intervals & Recurrence Monitoring 4.3 Secondary Prevention, Physical Activity, Nutrition & Wellness Guidance

6 Chapter 5: Carcinogenesis & Diagnostic Evaluation (Diagnosis and Staging)

5.1 Carcinogenesis: How Breast Cancer Develops and Spreads 5.2 Clinical Assessment, Diagnostic Imaging & BI-RADS Categorization 5.3 Breast Biopsy Modalities & Image-Guided Localization Techniques

7 Chapter 6: Pathology, Biomarkers & Genomic Testing (Diagnosis and Staging)

6.1 Histopathology: In Situ Carcinomas & Invasive Carcinoma Subtypes 6.2 Receptor Biomarkers (ER, PR, HER2, Ki-67) & Molecular Subtypes 6.3 Multigene Genomic Assays & Recurrence Risk Stratification

8 Chapter 7: Clinical & Pathologic Staging (Diagnosis and Staging)

7.1 AJCC TNM Staging System (Anatomic vs Prognostic Staging) 7.2 Staging Workup: When to Use MRI, CT, Bone Scan & PET

9 Chapter 8: Breast Surgery, Axillary Staging & Reconstruction (Treatment Modalities)

8.1 Breast-Conserving Surgery, Margin Standards & Mastectomy Techniques 8.2 Axillary Staging: Sentinel Lymph Node Biopsy vs. Axillary Dissection 8.3 Post-Mastectomy Reconstruction & Oncoplastic Surgery

10 Chapter 9: Radiation Therapy & Chemotherapy (Treatment Modalities)

9.1 Radiation Therapy: Whole Breast, Chest Wall, Regional Nodal & Partial Breast Irradiation 9.2 Neoadjuvant vs. Adjuvant Chemotherapy Principles & Standard Regimens

11 Chapter 10: Endocrine, HER2-Targeted & Novel Systemic Therapies (Treatment Modalities)

10.1 Endocrine Therapy: SERMs, Aromatase Inhibitors, Ovarian Suppression & SERDs 10.2 HER2-Targeted Monoclonal Antibodies, Antibody-Drug Conjugates & Kinase Inhibitors 10.3 CDK4/6 Inhibitors, PARP Inhibitors & Immune Checkpoint Blockade 10.4 Trop-2 Antibody-Drug Conjugates, PI3K/AKT/mTOR Inhibitors & New Oral SERDs

12 Chapter 11: Specific Conditions & Special Populations (Treatment Modalities)

11.1 Triple-Negative Breast Cancer: Treatment Considerations 11.2 HER2-Positive Breast Cancer: Treatment Considerations 11.3 Inflammatory Breast Cancer & Paget Disease of the Nipple 11.4 Phyllodes Tumors & Breast Angiosarcoma 11.5 Treatment Considerations for Special Populations

13 Chapter 12: Symptom Management & Supportive Care (Nursing Practice)

12.1 Acute Chemotherapy Toxicities, Supportive Regimens & Oncologic Emergencies 12.2 Lymphedema Pathophysiology, ISL Staging & Complete Decongestive Therapy (CDT) 12.3 Musculoskeletal Toxicities, Bone Health & Vasomotor/GSM Relief 12.4 Complementary & Integrative Modalities 12.5 Cancer Rehabilitation: Physical, Occupational & Pelvic Floor Therapy

14 Chapter 13: Oncologic Emergencies (Nursing Practice)

13.1 Oncologic Emergencies I: Spinal Cord Compression, Hypercalcemia, Tamponade & SVC Syndrome 13.2 Oncologic Emergencies II: Hypersensitivity & Anaphylaxis, Sepsis, Pleural Effusion & Thromboembolism

15 Chapter 14: Professional Practice, Clinical Trials & Self-Care (Nursing Practice)

14.1 Professional Practice: Guidelines, Ethics, Legislation, Outreach & Accreditation 14.2 Clinical Trials in Breast Oncology 14.3 Nurse Self-Care: Compassion Fatigue, Burnout, Moral Distress & Substance Use

16 Chapter 15: Psychosocial Dimensions of Care (Psychosocial Dimensions)

15.1 Psychosocial Distress, Coping, Grief & Palliative Care 15.2 Culture, Spirituality, Sexual & Gender Identity, Age & Healthcare Disparities 15.3 Family & Caregiver Dynamics 15.4 Altered Body Image 15.5 Reproductive & Sexual Health

8.2 Axillary Staging: Sentinel Lymph Node Biopsy vs. Axillary Dissection

Key Takeaways Explain This Topic AI

Sentinel lymph node biopsy (SLNB) utilizes dual-tracer mapping (Technetium-99m radiocolloid plus blue dye or indocyanine green) to identify the first draining lymph node from the tumor bed, achieving a false-negative rate below 5% to 7% in clinically node-negative early-stage breast cancer.

The landmark ACOSOG Z0011 randomized trial established that completion axillary lymph node dissection (ALND) can be safely omitted in women with cT1-T2 cN0 breast cancer undergoing breast-conserving surgery and whole-breast radiation with 1 or 2 positive sentinel nodes, showing no difference in 10-year locoregional control or overall survival.

Axillary lymph node dissection entails en bloc resection of Berg Level I and II nodes bounded by the axillary vein superiorly, latissimus dorsi laterally, and serratus anterior medially, and carries a 15% to 25% risk of chronic upper-extremity lymphedema.

In patients with initial node-positive disease receiving neoadjuvant systemic therapy, false-negative rates of SLNB are reduced below 10% by utilizing dual-tracer mapping, retrieving at least 3 lymph nodes, and performing targeted axillary dissection (TAD) to excise the pre-treatment clipped node.

Iatrogenic nerve injuries during axillary surgery present with distinct clinical syndromes: intercostobrachial nerve transection causes medial upper arm numbness, long thoracic nerve injury causes serratus anterior paralysis with scapular winging, and thoracodorsal nerve injury impairs shoulder adduction and downward pull.

Last updated: September 2026

Anatomical Principles and Techniques of Sentinel Lymph Node Staging

Regional axillary nodal status remains one of the single most influential prognostic determinants in early-stage invasive breast cancer, informing staging according to the AJCC TNM system and directing systemic adjuvant recommendations (chemotherapy, targeted biologicals, ovarian suppression) and locoregional radiation fields.

The Sentinel Lymph Node (SLN) Concept

The sentinel lymph node is defined as the first lymph node (or group of initial nodes) that directly receives afferent lymphatic drainage from the primary mammary neoplasm. Based on the ordered, sequential nature of lymphatic transit, if the sentinel node is histologically free of metastatic carcinoma, the remaining downstream non-sentinel axillary nodes are pathologically negative in greater than 95% to 98% of cases . Sentinel lymph node biopsy (SLNB) replaced routine completion axillary dissection as the standard of care for clinically node-negative (cN0) disease, eliminating the heavy morbidity of arm lymphedema and shoulder dysfunction in non-metastatic patients.

Dual-Tracer Mapping Methodology

Clinical guidelines strongly endorse the dual-tracer mapping technique , which combines a radiolabeled colloid with a vital blue dye or fluorescent agent to optimize sentinel node identification and minimize the false-negative rate (FNR):

Radiocolloid (Technetium-99m Sulfur Colloid) :

Injected intradermally, subareolarly, or peritumorally either the morning of surgery or the afternoon prior.

Filtered sulfur colloid particles (100 to 220 nm) migrate through lymphatic capillaries and become trapped within the reticuloendothelial sinuses of the sentinel nodes.

Intraoperatively, the surgeon utilizes a handheld acoustic gamma probe to identify radioactive 'hot' nodes through transcutaneous and direct tissue acoustic counts.

The 10% Rule : Any lymph node exhibiting radioactivity counts ≥10% of the most active ('hottest') sentinel node ex vivo is defined as a sentinel node and must be excised.

Vital Blue Dyes (Isosulfan Blue or Methylene Blue) :

Injected into the subareolar or peritumoral dermal plexus intraoperatively, followed by 5 minutes of gentle parenchymal massage to promote lymphatic uptake.

Dyes travel rapidly through superficial lymphatic trunks, visually staining afferent channels and sentinel nodes bright blue.

Any node that is visually blue or has a blue lymphatic channel entering it is categorized as a sentinel node.

Near-Infrared Fluorescence (Indocyanine Green [ICG]) :

Emerging optical mapping technique using ICG illuminated by near-infrared light cameras, providing real-time transcutaneous visualization of lymphatic channels without radiation exposure.

Clinical Safety Pearls Regarding Mapping Dyes

Isosulfan Blue (Lymphazurin) : Associated with IgE-mediated allergic reactions in roughly 1% to 2% of patients (severe anaphylaxis in well under 1%), presenting as 'blue hives' (generalized urticaria), acute bronchospasm, and profound cardiovascular collapse. Furthermore, intravascular absorption alters blood light absorbance at 660 nm, causing a transient, false drop in pulse oximetry (SpO2) readings to 85-90% despite normal arterial blood gas oxygen tension (PaO2). Nurses must recognize this benign optical artifact to prevent inappropriate hyperventilation or emergency airway interventions.

Methylene Blue : Extravasation or superficial intradermal injection can induce severe ischemic dermal necrosis and chronic skin ulceration. Methylene blue is a potent monoamine oxidase A (MAO-A) inhibitor; when administered to patients receiving serotonergic psychotropic medications (SSRIs, SNRIs), it carries a rare risk of precipitating life-threatening serotonin syndrome .

Indications and Absolute Contraindications for SLNB

Standard Indications : Clinically node-negative (cN0 by physical exam and axillary ultrasound) invasive breast carcinomas (T1 to T3); patients with extensive high-grade DCIS undergoing total mastectomy (because breast removal prevents performing an SLNB later if microinvasive or invasive carcinoma is unexpectedly discovered on permanent pathology).

Absolute Contraindications :

Inflammatory Breast Cancer : Malignant tumor emboli extensively plug dermal lymphatic channels, causing chaotic, unpredictable retrograde lymphatic diversion that yields an unacceptably high false-negative rate (>20-30%).

Clinically Overt, Biopsy-Proven Axillary Nodal Metastasis (cN1-N2) : Patients with palpably matted, fixed, or ultrasound-proven biopsy-positive nodes prior to surgery are not candidates for primary SLNB and require formal axillary clearing (unless undergoing neoadjuvant chemotherapy).